The impact of modern antitumor drug therapy on oncoepidemiological indicators of cervical cancer in Krasnoyarsk Krai

Introduction . Cervical cancer, a malignant tumor that develops from the lining of the cervix. The main etiological factor in the development of this process is highly oncogenic strains of human papillomavirus type 16 and 18. Cervical cancer is 9 th ranks in the prevalence of malignant neoplasms (MNEs) worldwide and 4 th in the female population. In 2024, 426 new cases of cervical cancer were detected in the Krasnoyarsk Territory, which is 2.6% in the overall structure of oncological pathology (14 th place) and 5.0% in the structure of female cancer incidence (6 th place). In the structure of the stages of cervical cancer in the Krasnoyarsk Krai, the proportion of patients with I–II established stages of cervical cancer was 58.1% in 2022, in 2024 has increased to 66.0%. In a dynamic assessment of late stages of cervical cancer, namely III–IV, they accounted for a total of 31.0% in 2020, in 2022 this has increased to 41.9%, which makes this pathology even more actual in terms of diagnosis and choice of treatment approaches. Aim . To evaluate the effectiveness of pembrolizumab immunotherapy in a patient with PD-L1-positive status, progressive cervical cancer after radical chemoradiotherapy and platinum-containing chemotherapy and its effect on the patient’s prognosis and epidemiological parameters of oncology. Materials and methods . The analysis of GLOBOCAN data and reference books “Malignant neoplasms in Russia” is conducted. The results of the studies of KEYNOTE-158 and KEYNOTE-826 were used, as well as our own data obtained from the results of patient treatment. Results . According to GLOBOCAN, cervical cancer ranks 4th among oncological diseases in women. In 2024 16.3 thousand new cases were identified in the Russian Federation. The Krasnoyarsk Krai demonstrates a high incidence rate. Modern treatment approaches, including the use of immunotherapy, have shown effectiveness and stabilization of the process after 19 courses. Conclusions . Pembrolizumab immunotherapy is effective in patients with PD-L1-positive status, recurrent or metastatic cervical cancer, allows to achieve long-term stabilization and improve the prognosis.